STOCK TITAN

Inogen (INGN) SEC Filings

INGN NASDAQ

Inogen SEC filings document a respiratory medical technology business that develops, manufactures, markets, sells, and rents respiratory products for homecare use. Results filings and annual proxy materials cover operating performance, executive compensation, director elections, board committees, equity plans, and stockholder voting matters.

Recent Form 8-K disclosures also record share repurchase authorization, leadership and compensatory arrangements, material governance agreements, and Regulation FD communications. The filing record ties these corporate actions to Inogen’s common stock, board oversight, and product portfolio in portable oxygen, airway clearance, stationary oxygen, and CPAP categories.

Rhea-AI Summary

Inogen Inc. said Kevin R.M. Smith’s roles as an officer and employee ended October 30, 2026. On November 16, Smith and the company entered a separation agreement that makes him eligible for severance benefits consistent with his Employment and Severance Agreement effective November 10, 2023, subject to his signing the agreement, its effectiveness and his continued compliance. The agreement also makes him eligible to earn a prorated fiscal 2026 annual bonus based on actual performance and provides for vesting of certain equity awards scheduled for December 1, 2026. Smith resigned from the board effective November 16; the company said his resignation was not related to a disagreement over its operations, policies or practices. The board’s authorized size decreased from nine directors to eight effective November 17, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.21%
Tags
current report
-
Rhea-AI Summary

Inogen Inc. (INGN) reported third-quarter 2026 revenue of $77.193 million, down 2.4% from a year earlier, and a net loss of $16.155 million versus $5.294 million. Portable-unit sales increased 5.9% to approximately 51,900 units. U.S. revenue rose 3.8%, while international revenue fell 9.0%; gross margin was 44.1%, compared with 45.7%.

On November 2, 2026, Inogen completed the sale to Rotech Healthcare Inc. of certain assets used or held for use solely in its U.S. oxygen rental business for an aggregate purchase price of up to $24.8 million, payable in six installments beginning January 4, 2027 and subject to post-closing reconciliation. The rental business is reported as discontinued operations.

On November 5, 2026, Inogen's board approved a cost reduction program expected to generate approximately $20 million in annualized savings, with about half in the fourth quarter of 2026 and the remainder throughout 2027; substantial completion is expected by year-end 2027. Effective November 2, its share repurchase authorization increased to $45 million and expires June 30, 2028. Nine-month net cash used in operating activities was $8.209 million, versus $10.273 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.88%
Tags
quarterly report
-
Rhea-AI Summary

Inogen Inc. (INGN) reported third-quarter continuing-operations revenue of $77.2 million, down 2.4% from $79.1 million. GAAP loss from continuing operations was $14.8 million versus $3.6 million; adjusted results were a $0.4 million loss versus $1.2 million of earnings. GAAP gross margin was 44.1%, compared with 45.7%.

Inogen completed the sale of its U.S. oxygen rental business to Rotech Healthcare Inc. on November 2, 2026, for estimated cash consideration of up to approximately $24.8 million, subject to post-closing reconciliation and payable in six installments. Its cost-reduction program is expected to generate approximately $20 million in annualized savings, with about half expected in fourth-quarter 2026 and the remainder throughout 2027; completion is expected by the end of 2027.

Andrew (“Andy”) P. Reding became president and CEO on October 30, 2026, succeeding Kevin R.M. Smith. His compensation includes a $700,000 annual base salary, a target annual bonus of 100% of salary prorated for 2026, and a one-time $300,000 cash bonus. Equity awards covering 337,500 shares are subject to committee approval and continued service through the grant date, with a 2027 grant planned. Full-year 2026 continuing-operations revenue guidance is $298 million to $301 million; adjusted loss guidance is $7 million to $8 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.93%
Tags
current report
Rhea-AI Summary

Inogen (INGN) agreed to sell Rotech Healthcare substantially all assets used solely in its U.S. oxygen rental business, including specified inventory and related patient records, for estimated consideration of up to approximately $24.8 million. The amount is subject to post-closing reconciliation and payable in six installments. Closing is subject to customary conditions and expected in the fourth quarter of 2026.

Inogen also signed a long-term product supply agreement with Rotech. The share repurchase amendment is effective only upon closing; it would increase the total authorization from $30.0 million to $45.0 million, including prior repurchases, and extend the program through June 30, 2028. Rental Business revenue was $24.3 million in the first half of 2026, down 9.8% year over year. Inogen expects to present the business as discontinued operations beginning with third-quarter 2026 results, subject to its final accounting analysis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.47%
Tags
current report
-
Rhea-AI Summary

Inogen Inc (INGN) reported that Mary E. Wright, its Vice President and Chief Accounting Officer, acquired 1,500 shares of Inogen common stock on September 1, 2026. The shares were acquired through the company’s 2014 Employee Stock Purchase Plan, bringing her directly held stake to 20,629 shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.55%
Tags
insider
-
Rhea-AI Summary

Inogen Inc (INGN) reported that executive vice president Kevin P. Smith completed multiple equity transactions on September 1, 2026, in connection with restricted stock units and the employee stock purchase plan, reported as made under a Rule 10b5-1 trading plan. An award of 18,136 restricted stock units was exercised into an equal number of common shares, with 8,671 of those shares withheld to satisfy tax withholding liability and 1,500 additional shares acquired through the 2014 Employee Stock Purchase Plan at $5.33 per share. Following the vesting event, 18,135 restricted stock units remain outstanding and subject to future vesting.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.55%
Tags
insider
Rhea-AI Summary

Inogen Inc (INGN) reports that CEO, President, and director Kevin Raymond Merrill Smith acquired 1,500 shares of common stock on September 1, 2026 through the company’s 2014 Employee Stock Purchase Plan at $5.33 per share. The filing shows he now directly owns 134,962 shares, with the transaction made under a Rule 10b5-1 trading plan.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.55%
Tags
insider
-
Rhea-AI Summary

Inogen, Inc. develops and rents respiratory products such as portable and stationary oxygen concentrators, airway clearance devices, and CPAP masks. For the three months ended June 30, 2026, revenue was 95,084 (amounts in thousands), up 3.0% from 92,277, driven by 5.5% growth in sales revenue and 14.8% growth in international sales, partly offset by an 11.8% decline in U.S. rental revenue due to fewer patients on service.

Total gross margin improved to 45.5% from 44.8%, as higher sales volumes and lower component and warranty costs lifted sales margins, while rental margins declined on higher logistics costs per patient. Operating expenses were 48,368, yielding a loss from operations of 5,096, compared with 6,129 a year earlier. Net loss for the quarter was 3,850 (basic and diluted EPS $(0.14)), and for the first six months net loss was 12,174 (EPS $(0.45)).

As of June 30, 2026, Inogen held 87,276 in cash and cash equivalents, 18,263 in marketable securities, and 1,303 in restricted cash, with total assets of 285,572 and stockholders’ equity of 174,864. Net cash used in operating activities improved to 3,739 for the first six months, from 12,440 in the prior-year period. Under a $30,000 share repurchase program authorized in February 2026, the company bought back and retired 1,145,150 shares for 7,498, leaving 22,502 available under the authorization.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.50%
Tags
quarterly report
-
Rhea-AI Summary

Inogen, Inc. reported second quarter 2026 results with revenue of $95.1 million, up 3.0% year-over-year, and raised full-year adjusted EBITDA guidance to approximately $4.0 million, representing a 48.1% increase from 2025 adjusted EBITDA of $2.7 million.

International sales were $41.3 million, up 14.8%, while U.S. sales and rentals declined, and total gross margin improved to 45.5% from 44.8% a year earlier. GAAP net loss was $3.9 million compared with $4.2 million, and adjusted EBITDA increased to $2.4 million from $2.1 million. The company generated $2.9 million of operating cash flow in the quarter and ended June 30, 2026 with $106.8 million in cash, cash equivalents, marketable securities, and restricted cash and no debt, after repurchasing 1,145,150 shares for $7.5 million in the first half.

Operationally, Inogen reported publication of its QuOTE assessment tool for Long-Term Oxygen Therapy, launch of the Rove 6 portable oxygen concentrator in Canada, completion of Last Patient Last Visit for the Simeox H SCOPE Study in China, and the appointment of a new Chief Operating Officer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.78%
Tags
current report
Rhea-AI Summary

Reding Andrew P. reported acquisition or exercise transactions in this Form 4 filing.

Inogen Inc executive Andrew P. Reding, EVP and COO, received a grant of 130,000 restricted stock units. Each unit represents the right to receive one share of Inogen common stock. One-third of the units will vest one year from September 1, 2026, with the remaining two thirds vesting in equal annual installments on the same date in subsequent years, subject to his continued service.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.62%
Tags
insider

FAQ

How many Inogen (INGN) SEC filings are available on StockTitan?

StockTitan tracks 56 SEC filings for Inogen (INGN), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Inogen (INGN)?

The most recent SEC filing for Inogen (INGN) was filed on November 19, 2026.